NASDAQ:GLMD - Nasdaq - IL0011313900 - Common Stock - Currency: USD
NASDAQ:GLMD (2/21/2025, 8:23:54 PM)
2.7031
+0.15 (+6%)
The current stock price of GLMD is 2.7031 USD. In the past month the price decreased by -8.06%. In the past year, price decreased by -37.88%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
GALMED PHARMACEUTICALS LTD
16 Tiomkin Street
TEL AVIV-YAFO 6578317 IL
CEO: Allen Baharaff
Employees: 6
Company Website: https://www.galmedpharma.com
Investor Relations: http://galmedpharma.investorroom.com/
Phone: 97236938448
The current stock price of GLMD is 2.7031 USD. The price increased by 6% in the last trading session.
The exchange symbol of GALMED PHARMACEUTICALS LTD is GLMD and it is listed on the Nasdaq exchange.
GLMD stock is listed on the Nasdaq exchange.
7 analysts have analysed GLMD and the average price target is 12.24 USD. This implies a price increase of 352.81% is expected in the next year compared to the current price of 2.7031. Check the GALMED PHARMACEUTICALS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GALMED PHARMACEUTICALS LTD (GLMD) has a market capitalization of 4.08M USD. This makes GLMD a Nano Cap stock.
GALMED PHARMACEUTICALS LTD (GLMD) currently has 6 employees.
GALMED PHARMACEUTICALS LTD (GLMD) has a support level at 2.61 and a resistance level at 2.71. Check the full technical report for a detailed analysis of GLMD support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GLMD does not pay a dividend.
GALMED PHARMACEUTICALS LTD (GLMD) will report earnings on 2025-04-02, after the market close.
GALMED PHARMACEUTICALS LTD (GLMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-39.12).
The outstanding short interest for GALMED PHARMACEUTICALS LTD (GLMD) is 0.46% of its float. Check the ownership tab for more information on the GLMD short interest.
ChartMill assigns a fundamental rating of 3 / 10 to GLMD. No worries on liquidiy or solvency for GLMD as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months GLMD reported a non-GAAP Earnings per Share(EPS) of -39.12. The EPS increased by 68.95% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -30.19% | ||
ROE | -34.3% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to GLMD. The Buy consensus is the average rating of analysts ratings from 7 analysts.